Even een stukje uit het laatste earnings call transcript wat 2020 betreft:
What is the growth story for 2020? We think of 3 broad value drivers. First, 2020 is the year of bringing RNAi outside the liver to address a raft of new unmet medical needs. We are clear leaders in this endeavor, and I believe we will have clinical proof-of-concept to silence target genes in lung and solid tumors by the end of the year. Just look at what we have done in hepatocytes, and we believe we can do the same in lung and solid tumors. This model of rapidly expanding our pipeline in new cell types could offer powerful new options for countless patients and enabled the promise of continued value growth. Second, we are looking to advance multiple liver-targeted programs into mid- and late-stage studies including up to 3 potentially pivotal clinical trials. And third, we expect to continue to expand the reach of the TRiM platform and enable access to an important new cell type, skeletal muscle. It will mean a lot to our business if we were able to execute in these areas. By the end of the year, we could have 10 TRiM-enabled drug candidates in the clinic, 8 of which could be wholly-owned, targeting up to 4 different cell types with up to 3 candidates in potentially pivotal studies. Let those numbers sink in for a moment. I don't believe there is a company our size anywhere with this type of reach. And remember that this is all built on a single, scalable platform.